Related Experiment Video
Updated: May 10, 2025
Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
Identification of novel Mycobacterium tuberculosis leucyl-tRNA synthetase inhibitors with antibacterial activity
Galyna P Volynets1,2, Olga I Gudzera3, Segiy S Lukashov1
1Department of Medicinal Chemistry, Institute of Molecular Biology and Genetics, The NAS of Ukraine, Kyiv, Ukraine.
Background:
Tuberculosis has become the world's most lethal infectious disease. A major challenge in treating tuberculosis is the multidrug resistance of Mycobacterium tuberculosis to existing antibiotics. Therefore, there is an urgent need to discover new antituberculosis agents with unexploited mechanisms of action. The aim of the work was to develop inhibitors of mycobacterial leucyl-tRNA synthetase (LeuRS) with antibacterial activity.
Materials And Methods:
The virtual screening of compound collection containing about 250,000 ligands into aminoacyl-adenylate binding site of M. tuberculosis LeuRS was performed with AutoDock 4.2 software. The inhibitory activity of compounds toward recombinant LeuRS was studied in aminoacylation assay using 14C-labeled L-leucine. Antibacterial activity was investigated toward M. tuberculosis H37Rv strain under four different conditions.
Results:
According to the data of biochemical screening, we have found M. tuberculosis LeuRS inhibitors among N-(5-Benzyl-thiazol-2-yl)-2-(1-phenyl-1H-tetrazol-5-ylsulfanyl)-acetamide deivatives, which decrease enzyme activity with IC50 values in micromolar range. The most promising compound, N-(5-Benzyl-thiazol-2-yl)-2-[4-(4-methoxy-phenyl)-1H-tetrazol-5-ylsulfanyl]-acetamide, reveals potent antibacterial activity with the best minimum inhibitory concentration (MIC) value of 4.7 µM.
Conclusion:
N-(5-Benzyl-thiazol-2-yl)-2-(1-phenyl-1H-tetrazol-5-ylsulfanyl)-acetamide scaffold can be valuable for further biological research and chemical optimization.
